TriGemX Bio
Biotech company developing a first-in-class oral medicine for the treatment of migraine.
TriGemX Bio is a biotech & life sciences company based in New York, US, founded in 2015. It has raised $94 million in disclosed funding. Its latest round was an Undisclosed stage of $94 million in October 2026.
Overview
No overview yet. It is written from sources once there are enough of them.
Funding
Total disclosed: $94M across 1 round. Computed only from sourced rounds.
| Date | Company | Amount | Stage | Lead | Other investors | Sector | Sources |
|---|---|---|---|---|---|---|---|
| $94M | Undisclosed stage | The Column Group, TCG Crossover, Viking Global Investors | — | Biotech & Life Sciences | 1 |
- TriGemX Bio$94M
Led by The Column Group, TCG Crossover, Viking Global Investors
Investors
Questions and answers
What does TriGemX Bio do?
Biotech company developing a first-in-class oral medicine for the treatment of migraine.
How much has TriGemX Bio raised?
TriGemX Bio has raised $94 million in disclosed funding across 1 round tracked by OSH.
Who has invested in TriGemX Bio?
Investors in TriGemX Bio include The Column Group, TCG Crossover, and Viking Global Investors.
When and where was TriGemX Bio founded?
TriGemX Bio was founded in 2015 and is based in New York, US.
Timeline
Founded
Sources
- 1.The AlleyWatch Startup Daily Funding Report: 10/2/2026 — AlleyWatch, Oct 2, 2026